CJC-1295 No DAC + Ipamorelin 10mg (CJC-1295 DAC)

Ipamorelin is among the most selective growth hormone (GH) secretagogues known and a potent agonist at the ghrelin, or growth hormone secretagogue, receptor. It has been researched heavily across a number of settings, with reported improvements in bone health, in muscle repair and development, in insulin release from the pancreas, and in bowel motility and gastric function.

CJC-1295 also causes GH to be released, but it does so by stimulating the growth hormone releasing hormone receptor instead. It is likewise highly selective, and has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth and development. Combining the two peptides may produce enhanced effects, since they stimulate the growth hormone axis through two different mechanisms. Research in animal models using both is likely to show increased benefit without substantially increased side effects.

Ipamorelin is likely to raise baseline levels of GH, which would let CJC-1295 produce higher peaks and higher troughs alike while normal pulsatile secretion of growth hormone is preserved. The net effect of combining them would be a higher set point for the ordinary ebb and flow of GH, and with it improved lean body mass, better muscle development, improved use of insulin and better metabolic function overall.

This is a combination vial containing modified GRF(1-29), commonly labelled CJC-1295 without DAC, together with ipamorelin, stated on the listing as 5mg of each in a 10mg vial. Unlike most blends in this catalogue, the pairing has a specific and defensible pharmacological rationale rather than a general appeal to complementary effects.

Growth hormone release from the pituitary somatotroph is governed by at least two distinct receptor systems. The GHRH receptor responds to growth hormone releasing hormone from the hypothalamus, and modified GRF(1-29) is an agonist there. The growth hormone secretagogue receptor GHS-R1a responds to ghrelin, and ipamorelin is a selective agonist at that one. The two receptors sit on the same cell and are engaged by different ligands, so the constituents are not redundant.

The argument for combining them is that engaging both pathways at once should produce a larger secretory response than either alone, since one raises the drive on the somatotroph while the other acts through a separate signalling route. That is a coherent mechanistic proposition. It has not been tested as a combination in any adequately powered human study, so it should be read as a rationale rather than as a demonstrated effect.

Most multi-peptide vials are justified by pointing at compounds that all seem helpful. This one is different and deserves credit for it. Two separate receptor systems control growth hormone release from the same cell, and this vial contains one agonist for each.

That is a genuine reason to expect more than either alone would produce, and it is the reason the pairing appears throughout the literature discussion of these compounds rather than only in product listings. The receptors are pharmacologically distinct, so the constituents cannot be substitutes for one another.

What is missing is the study. No adequately powered human work has measured the combination against either constituent alone, so the size of any additional effect, and whether it exists at scale, is unmeasured. A good rationale is not a result.

The listing specifies no DAC, which is the important qualifier. CJC-1295 with DAC carries a maleimidopropionyl group that binds albumin covalently and gives a half-life of six to eight days. Without it, the same peptide backbone clears in roughly half an hour.

That difference of about two orders of magnitude changes what the blend does. Paired with ipamorelin, which also clears quickly, the no-DAC version produces a discrete pulse in which both arms are active at once. The DAC-bearing version would instead provide continuous GHRH receptor stimulation with an intermittent secretagogue pulse superimposed, which is a different intervention.

Because CAS 863288-34-0 designates the DAC-bearing molecule and is frequently printed on the other, a blend certificate is a place this error propagates easily. The mass settles it: near 3368 for the version in this vial, near 3647 with the DAC group.

The two constituents differ by roughly 2650 daltons, which is a very large separation. A 711.9 dalton pentapeptide and a 3368 dalton 29-mer cannot be confused with each other or with plausible impurities of each other, so a mass spectrum resolves the composition immediately.

The stated equal ratio again makes quantification the simplest case. As with the other two-component vial in this catalogue, a supplier unwilling to report per-constituent quantification for an equal-ratio pair of well-separated species is avoiding an easy measurement.

Neither compound is approved in any jurisdiction and both appear on prohibited lists in competitive sport. Material supplied for research is for in-vitro laboratory use only.

Neither constituent carries a reactive maleimide, which is one practical advantage of the no-DAC version in a blend: thiol-containing buffers and reducing agents do not compromise either molecule's identity, whereas they would consume the DAC group on the alternative construct.

Ipamorelin contains non-proteinogenic residues, alpha-aminoisobutyric acid and two D-amino acids, so enzymatic sequencing behaves unusually on it. Both constituents are C-terminally amidated and their free acids differ by one dalton, which is worth noting when reading a high-resolution mass trace of the mixture.